Human Immunoglobulin G (IgG) Concentrate
A purified fraction of human blood plasma containing high levels of Immunoglobulin G antibodies, used therapeutically to treat primary immunodeficiencies and autoimmune disorders. It falls under HTS 3002.12.0090 as an immunological product derived from blood fractions, prepared for therapeutic use via biotechnological purification processes. This excludes simple blood products without specific immunological modification.
Import Duty Rates by Country of Origin
| Origin Country | MFN Rate | Ch.99 Surcharges | Total Effective Rate |
|---|---|---|---|
| 🇨🇳China | Free | — | Free |
| 🇲🇽Mexico | Free | — | Free |
| 🇨🇦Canada | Free | — | Free |
| 🇩🇪Germany | Free | — | Free |
| 🇯🇵Japan | Free | — | Free |
Alternative Classifications
This product could be classified differently depending on its characteristics or intended use.
If specifically a vaccine preparation
Vaccines, even if containing blood-derived antigens, shift to 3002.13 as they are cultures or toxins for immunization.
If for unmodified human blood sera
Unmodified or minimally processed blood sera without specific immunological fractionation fall under other immunological products.
If isolated as peptide/protein for non-therapeutic lab use
Highly purified blood-derived peptides not prepared for direct therapeutic use may classify as chemical products in Chapter 35.
Not sure which classification is right?
Our AI classifier can analyze your specific product and recommend the correct HTS code with confidence.
Import Tips & Compliance
• Verify FDA biologics license and ensure cold chain documentation (2-8°C) during import to maintain efficacy
• Provide certificates of analysis confirming immunological activity and absence of contaminants like prions
• Avoid misclassification as general plasma; include proof of fractionation process to confirm HTS 3002 placement
Related Products under HTS 3002.12.00.90
Cytomegalovirus (CMV) Hyperimmune Globulin
Hyperimmune plasma fraction enriched with CMV-specific antibodies for preventing CMV infection in transplant patients. Falls under HTS 3002.12.0090 as an other blood fraction/antisera prepared for prophylactic use through plasma fractionation. It meets the definition of immunological products from human blood.
Botulinum Toxin Type A Immune Globulin
Antitoxin derived from human plasma fractions containing antibodies against botulinum toxin, used to treat infant botulism. Classified in HTS 3002.12.0090 as an immunological blood fraction for therapeutic neutralization of toxins. It involves biotech purification of specific antisera.
Tetanus Immune Globulin (TIG)
Human blood fraction providing passive immunity against tetanus toxin for wound management. Under HTS 3002.12.0090 as other blood fraction antisera prepared for therapeutic use. Involves hyperimmunization and plasma fractionation.
Hepatitis B Immune Globulin (HBIG)
Plasma-derived antibodies specific to hepatitis B surface antigen for post-exposure prophylaxis in high-risk cases. Classifies in HTS 3002.12.0090 as an immunological blood fraction/antiserum. Biotechnological pooling and purification ensure specificity.
Varicella Zoster Immune Globulin (VZIG)
Human immune globulin enriched for varicella-zoster virus antibodies to prevent severe chickenpox in immunocompromised patients. HTS 3002.12.0090 for other specific antisera from blood fractions. Prepared via donor plasmapheresis and affinity purification.
Anti-Rh(D) Immunoglobulin Injection
A blood fraction containing antibodies against Rh(D) antigen, administered prophylactically to prevent hemolytic disease in newborns. Classified in HTS 3002.12.0090 as an antiserum derived from human plasma via biotechnological processes for therapeutic use. It targets specific immunological responses rather than general blood components.